Activation of the epidermal growth receptor (ErbB1) occurs within minutes of a radiation exposure. Immediate downstream consequences of this activation are currently indistinguishable from those obtained with growth factors (GF), e.g. stimulation of the pro-proliferative mitogenactivated protein kinase (MAPK). To identify potential dierences, the eects of GFs and radiation on other members of the ErbB family have been compared in mammary carcinoma cell lines diering in their ErbB expression pro®les. Treatment of cells with EGF (ErbB1-speci®c) or heregulin (ErbB4-speci®c) resulted in a hierarchic transactivations of ErbB2 and ErbB3 dependent on GF binding speci®city. In contrast, radiation indiscriminately activated all ErbB species with the activation pro®le re¯ecting that cell's ErbB expression pro®le. Downstream consequences of these ErbB interactions were examined with MAPK after speci®cally inhibiting ErbB1 (or 4) with tyrphostin AG1478 or ErbB2 with tyrphostin AG825. MAPK activation by GFs or radiation was completely inhibited by AG1478 indicating total dependance on ErbB1 (or 4) depending on which ErbB is expressed. Inhibiting ErbB2 caused an enhanced MAPK response simulating an ampli®ed ErbB1 (or 4) response. Thus ErbB2 is a modulator of ErbB1 (or 4) function leading to dierent MAPK response pro®les to GF or radiation exposure. Oncogene (2001) 20, 1388 ± 1397.
Introduction
The ErbB receptor Tyr kinases (RTK) represent an interactive network of 170 ± 190 kD transmembrane proteins, with binding sites for ligands of the epidermal growth factor (EGF) family at the extracellular NH 2 -terminal domain. The cytoplasmic, COOH-terminal portions of the receptors carry Tyr, Ser, and Thr residues, the phosphorylation states of which are critical for their signaling functions (Earp et al., 1995; Qian et al., 1994; Riese and Stern, 1998) . Receptor dimerization upon GF binding results in activation of EGF receptor (ErbB1) and other ErbB species seen as receptor phosphorylation at de®ned Tyr residues through intrinsic kinase activity (Earp et al., 1995; Gamett et al., 1997; Graus-Porta et al., 1997; Riese and Stern, 1998) . The hierarchy of interactions between the ErbB receptors involves both homo-and heterodimer formation and is determined by the speci®cities of ErbB1, -3, and -4 for de®ned GFs (Earp et al., 1995; Gamett et al., 1997; Graus-Porta et al., 1997; Riese and Stern, 1998 ). Based on current information, only ErbB1 and ErbB4 express both GF binding and functional cytoplasmic kinase domains. ErbB2 is a constitutively active receptor for which a GF ligand has not yet been identi®ed (Graus-Porta et al., 1997; Huang et al., 1998) . In contrast, ErbB3 shares GF binding speci®city with ErbB4 but lacks intrinsic kinase activity. Because of these properties, ErbB2 and ErbB3 may primarily function as modulators of ErbB1 and ErbB4 activities (Plowman et al., 1996; Qian et al., 1994; Riese and Stern, 1998) .
The relative expression levels and activities of the dierent ErbB molecules in a given cell can determine the balance between cytoprotective and cytotoxic responses to ErbB activation by GFs and cytotoxic agents . As a result of receptor activation, downstream signals are channeled through adaptor proteins and exchange factors to the cytoprotective mitogen-activated protein kinase (MAPK)/phosphatidyl inositol-3-kinase (P13K), and the stress pathways invovling activation of Jun-Nterminal kinase (JNK) and p38 kinase (reviewed in Schmidt-Ullrich et al., 1999 .
In carcinoma and malignant glioma cells the ErbB receptors play critical roles in facilitating autocrine growth regulation (Frederick et al., 2000; Gamett et al., 1995; Graus-Porta et al., 1997; Huang et al., 1998; Kern et al., 1994; Reardon et al., 1999; Riese and Stern, 1998) . There is also increasing evidence that ErbB receptors participate in the responses of tumor cells to genotoxic agents, such as ionizing radiation (e.g. O'Rourke et al., 1998) . This is re¯ected in the fact that single and repeated radiation exposures, as applied during clinical radiotherapy, can activate ErbB RTKs and result in cytoprotective and cytotoxic signals mediating overall cellular responses of proliferation and apoptosis, respectively (Earp et al., 1995; O'Rourke et al., 1998; Reardon et al., 1999; SchmidtUllrich et al., 2000; Verheij et al., 1996) . The discovery that radiation-induced ErbB1 activation can initiate proliferation through the MAPK cascade has not only identi®ed a mechanism underlying accelerated repopulation but has also opened new avenues for therapeutic intervention using ErbB1 as a target (Akimoto et al., 1999; Huang et al., 1998; Schmidt-Ullrich et al., 1997) . While radiation exerts similar eects as GFs with respect to receptor activation there are fundamental dierences. GFs induce activation responses through a hierarchy of primary and secondary reactions that are driven by the speci®cities of receptor-GF interactions. In contrast, radiation can be expected to exert similar eects on all ErbB receptors and, therefore, indiscriminately activate all ErbB molecules expressed by a given tumor cell. If the varied expression and activation pro®les of ErbB receptors determine the activation of distinct response pathways, radiation and GFs could generate qualitatively and quantitatively dierent signals along cytoprotective and cytotoxic pathways. This study examines radiation and GF eects in two autocrine growth regulated mammary carcinoma cells (MCC) expressing dierent ErbB RTK pro®les. We describe dierences in the interactions between ErbB1 or ErbB4 with ErbB2 which result in distinct MAPK activation responses.
Results

ErbB RTK expression profiles in human carcinoma cells
As previously described, exposure of human MCCs and SCCs to ionizing radiation in the clinically relevant dose range of 1 ± 5 Gy activates ErbB1 within minutes and results in signaling along the MAPK and JNK cascades Schmidt-Ullrich et al., 1996 . The focus of the present study was to examine in more detail the role of ErbB1 and other ErbB RTKs in cellular radiation responses. Because of the established similarities, we continue to compare radiation-induced activation with that of GFs. This study was initiated by ®rst establishing the ErbB RTK expression pro®les of dierent carcinoma cells.
Under the conditions employed, MDA cells expressed similar levels of ErbB1 and ErbB2 receptors and substantially lower levels of ErbB3 (Figure 1 ). In comparison, A431 SCCs expressed higher levels of ErbB1 consistent with previous reports (Gamett et al., 1995; Gulliford et al., 1997; Riese and Stern, 1998) ; the relative expression levels of ErbB2 and ErbB3 proteins were similar to those in MDA cells. In both cell lines ErbB4 protein was not detected by immunoprecipitation ( Figure 1 ). As an example for varied expression of ErbB RTKs by carcinoma cell lines, we also included T47D MCCs into our analyses. These cells expressed comparatively high levels of ErbB4 and ErbB2 with lower amounts of ErbB3 and undetectable levels of ErbB1 protein (Figure 1 ).
GF-induced activation of ErbB RTKs in human carcinoma cells
Since the ErbB receptor expression pro®les varied most signi®cantly between MDA and T47D MCCs, the eects of GF and radiation exposure on ErbB interactions and critical downstream responses were studied in these two cell lines. Exposure of MDA cells to EGF resulted in a maximum 16-fold activation of ErbB1 (Figure 2a) . The 1.7-fold increase in ErbB2 Tyr phosphorylation in this experiment re¯ected the lower end of the extent of transactivation that was as high as eightfold (see Figures 4 and 5 for additional data). The increased Tyr phosphorylation of ErbB2 resulted from transactivation with ErbB1, since EGF cannot directly activate ErbB2 (Earp et al., 1995) . No activation of ErbB3 was detected under the conditions employed.
Treatment of T47D cells with HRG, a ligand for both ErbB3 and ErbB4, resulted in similar 4 20-fold stimulations of ErbB3 and ErbB4 phospho-Tyr levels ( Figure 2b) . As with the MDA cells, the simultaneous 1.6 ± 2.0-fold stimulation of ErbB2 was likely to re¯ect transactivation. Despite our inability to demonstrate the presence of ErbB1 protein, a modest 1.5-fold transactivation of ErbB1 suggested low level expression of this receptor, since the detection by mAb of multiple Tyr phosphorylation sites was likely to be more sensitive than that of protein. 
Radiation-induced ErbB activation
The ErbB RTK activation by GFs requires speci®c ligand-receptor interactions, whereas radiation is expected to indiscriminately activate ErbB receptors due to the random nature of ionization events. For this reason we compared the radiation-and GF-induced ErbB activation pro®les. The radiation dose of 2 Gy was selected since this is within the clinical range and in previous experiments the ErbB1 response to radiation was shown to saturate between 2 ± 5 Gy in all cells examined (Schmidt-Ullrich et al., 1996; Todd et al., 1999; Reardon et al., 1999; Dent et al., 1999) . The exposure of MDA cells to 2 Gy resulted in similar and simultaneous threefold activations of both ErbB1 and ErbB2 ( Figure 3a ) and a slightly lower twofold activation of ErbB3. In seven independent experiments, the average fold activations for ErbB1 and ErbB2 were 2.6+0.7 (P5.00002) and 2.4+0.9 (P5.002), respectively. The average radiation-induced activation of ErbB3 in three independent experiments was 2.1+00.5 (P5.02). Similar early (1 ± 2 min postirradiation) changes in ErbB receptor Tyr phosphorylation were also seen with T47D cells as shown in the representative experiment in Figure 3b . In three independent experiments radiation induced 2.8+0.3 (P5.0005), 2.1+0.4 (P5.01), and 2.3+0.4 (P5.005) fold increases in Tyr phosphorylation of ErbB4, ErbB3, and ErbB2, respectively in T47D cells. A later increase in Tyr phosphorylation of the ErbB receptors in T47D (5 10 min) probably re¯ects initiation of a radiation-induced, but ligand-dependent second phase of ErbB phosphorylation as previously reported .
Differences in ErbB receptor response profiles after exposure of cells to GFs or radiation
The activation pro®les of ErbB receptors in MDA and T47D cells after EGF and HRG treatment, respectively, were characterized by substantially dierent levels of enhanced Tyr phosphorylation. The strongest response was seen for those ErbB receptors that bind ligand with highest anity. This was supported by the ®ndings that EGF did not stimulate Tyr phosphorylation of ErbB4 (data not shown) and HRG exerted a relatively small eect on ErbB1 phosphorylation ( Figure 2b ). Therefore, the activation pro®les induced by GF are driven by receptor-ligand interaction and are independent of ErbB expression. In comparison, radiation-induced ErbB receptor activation is fundamentally dierent. Although the degree of activation is less than that obtained with GFs, radiation induces an indiscriminate activation of ErbB receptors as demonstrated by similar increases in Tyr phosphorylation of all receptors expressed by a given cell. This ®nding suggests that the response to radiation is primarily determined by the ErbB expression pro®le of that cell (Figure 3a,b) .
The indiscriminate ErbB activation by radiation precluded a direct analysis of transactivation between ErbB molecules. However, these secondary receptor interactions between ErbB1/ErbB4 and ErbB2 were measurable since GF-mediated enhanced Tyr phosphorylation of ErbB2 can only occur through transactivation due to a lack of ligand binding sites for ErbB2 (Earp et al., 1995) . The extent of heterodimerization was quanti®ed in MDA cells through exposure to increasing concentrations of the two physiological ligands, EGF and TGF-a, at concentrations between 1 and 100 ng/ml (Figure 4a) . Similarly, T47D cells were exposed to HRG over the same concentration range (Figure 4b ). In MDA and T47D cells, maximal 16-and 9-fold activations of ErbB1 and ErbB4 Tyr phosphorylation, respectively, were observed after 10 min exposures to GF. Under these conditions, secondary transactivations of ErbB2 amounted to maximum 6.8-(MDA) and 4.0-(T47D) fold increases in Tyr phosphorylation (Figure 4a,b) .
Quantitative aspects of ErbB1/ErbB2 interactions after exposure to radiation or EGF were more fully analysed in seven independent experiments with MDA cells ( Figure 5 ). The radiation-induced activations of ErbB1 and ErbB2 were measured as similar & twofold increases in Tyr phosphorylation. In contrast, EGF induced a 410-fold activation of ErbB1 and an average sixfold stimulation of ErbB2 as a result of transactivation. Statistical analyses by a two sample student's t-test revealed dierential ErbB1 and ErbB2 activation by EGF (P5.018) but no signi®cant dierence in their activations by radiation (P5.817). This data demonstrated the distinctly dierent mechan- . Quantitatively similar stimulations of both of ErbB1 and ErbB2 were observed after radiation relative to the GF-induced hierarchic receptor responses driven by the speci®cities of GF-ErbB receptor interactions.
The role of ErbB1 and ErbB2 function on receptor activation by GF and radiation
We next examined the relative role of ErbB receptors on GF-and radiation-induced receptor interactions. These studies were conducted with MDA cells in which the functions of ErbB1 and ErbB2 were selectively inhibited by the tyrphostins AG1478 and AG825, respectively (Fry et al., 1994; Levitzki and Gazit, 1995; Tsai et al., 1996) . Our previous studies (SchmidtUllrich et al., 1997; Todd et al., 1999) were con®rmed by the results in Figure 6b demonstrating that AG1478 completely inhibited basal, ligand-and radiationinduced activation of ErbB1. Independent control experiments armed that AG1478 did not aect basal ErbB2 phosphorylation as predicted by the 430 000-fold dierence in IC50 values for ErbB1 and ErbB2 (data not shown; Levitzki and Gazit, 1995; Tsai et al., 1996) . In contrast inhibition of ErbB2 function by AG825 eliminated ErbB2 Tyr phosphorylation ( Figure  6c ) but increased by an average 2.4-fold basal ErbB1
Tyr phosphorylation (Figure 6a,d ; P5.05). While the GF-and radiation-induced ErbB1 Tyr phosphorylation levels were also always higher under conditions of ErbB2 inhibition, these enhancements did not reach statistical signi®cance (Figure 6d ). These results were consistent with the relative inhibitor selectivity of AG825 for ErbB2. Furthermore, these results demonstrated that inhibiting ErbB2 resulted in a compensatory activation of ErbB1 suggesting a possible negative modulating role for ErbB2 on ErbB1 function (Gulliford et al., 1997) .
ErbB RTK function and MAPK responses in MDA and T47D cells
In de®ning the biological importance of ErbB1 and ErbB2 function on radiation-induced cellular responses the receptor activation pro®les have been linked to dierences in downstream signals. As a downstream target, we selected MAPK, a previously identi®ed mediator of cytoprotective responses after radiation (see below; Reardon et al., 1999) . We have demonstrated that substantial dierences in ErbB1 activation levels obtained after EGF and radiation exposure of cells nonetheless result in similar stimulations of MAPK .
The conditions for these studies were identical to those used in the experiments of Figure 6 for analysis ErbB Tyr phosphorylation. Radiation and EGF induced signi®cant 1.6-and threefold activations of MAPK, a phasic response that was maximal at about 5 min and returned to basal levels within 10 min (Figure 7a,b) . This initial activation was followed by a more protracted increase in MAPK activity after exposure of MDA cells to EGF (Figure 7b ; . Importantly, both the EGF and radiation responses are completely eliminated by inhibiting ErbB1 function with AG1478 (Figure 7a,b) . Almost identical, but quantitatively more pronounced responses were observed for T47D cells after treatment with HRG and radiation, including the elimination of these responses by pre-treatment of cells with AG1478 (Figure 8a,b) . This data further support the conclusion that ErbB1 and ErbB4 play analogous roles in MDA and T47D cells in respect to MAPK activation.
Inhibition of ErbB2 function with AG825 prior to GF or radiation exposure consistently elevated basal MAPK activity and caused a large enhancement of the ErbB1-dependent stimulation of MAPK (Figures 7 and  8) . Furthermore, the MAPK response pro®les after radiation and GF exposure were signi®cantly altered. EGF-induced phasic ErbB1 activation was converted by AG825 into a sustained ®vefold activation. In the case of radiation, the 5 min phasic activation was converted into a broad threefold activation lasting for 60 min. Qualitatively similar modi®cations were observed for T47D cells, in which inhibition of ErbB2 enhanced the ErbB4-dependent MAPK activity. These ®ndings were also consistent with with enhanced ErbB1 activation levels observed after AG825 treatment of MDA cells (Figure 6 ). Results from seven independent experiments were averaged and presented as the mean +s.d. Activation of ErbB1 (dark bars) and ErbB2 (shaded bars) was monitored as tyrosine phosphorylation normalized with respect to untreated controls. Experimental treatments were: a 5 min exposure to 10 ng/ml EGF or at peak phosphorylation after a 2 Gy radiation exposure. Dierential activations of ErbB1 and ErbB2 by EGF and radiation were statistically evaluated by a two sample student's t-test. Statistical signi®cance was established for dierential ErbB1 and ErbB2 activation by EGF (*P50.018). There was no statistically signi®cant dierence in ErbB1 and ErbB2 activation by radiation (**P50.817)
Discussion
The results presented herein underscore previous ®ndings from our laboratory identifying the critical role of plasma membrane-associated ErbB RTKs in the radiation response of autocrine growth-regulated carcinoma cells. We now demonstrate that the ErbB expression pro®le of carcinoma cells can determine the interactions between dierent ErbB RTKs. In addition, the data provides the ®rst evidence for distinct ErbB response pro®les of cells after exposure to GFs or radiation. GFs induce a hierarchic activation initiated by homodimerization/activation of those ErbB species primarily interacting with given GF. Secondary activation of other ErbB receptors occurs through heterodimerization. In contrast, ionizing radiation activates indiscriminately all ErbB molecules expressed by a given carcinoma cell, thus placing greater importance on the relative expression levels of ErbB receptors. Thus, the GF response is driven by ErbB expression and receptor-ligand speci®cities whereas the radiation response may primarily be determined by cellular ErbB expression pro®les. The importance of these dierences in ErbB receptor interaction responses is further emphasized by distinct MAPK response pro®les after exposure of cells to GFs or radiation Park et al., 1999) .
The apparent indiscriminate activation of dierent ErbB molecules by radiation raises questions concerning the underlying activation mechanism and whether alternative, ErbB-independent pathways exist for radiation-induced downstream signaling. One likely activation mechanism we are investigating involves inhibition of protein Tyr phosphatases (SchmidtUllrich et al., 1999 (SchmidtUllrich et al., , 2000 . Previous studies have demonstrated that reactive oxygen (e.g. H 2 O 2 ) oxidizes a Cys in the active sites of most all protein Tyr phosphatases, thereby inhibiting phosphatase activity. One consequence of this inhibition is the apparent stimulation of ErbB1 as indicated by its enhanced Tyr phosphorylation (e.g. Bae et al., 1997; Denu and Tanner, 1998) . Such a mechanism also applies to other Tyr kinases whose activities are counter-balanced by apposing Tyr phosphatases. As a consequence in cells not expressing ErbB receptors, radiation-induced MAPK activation may still be observed but involving some other Tyr Kinase-Tyr phosphatase couple. It should also be noted that the catalytic activity of the dual speci®city protein phosphatase, MKP-1, that dephosphorylates and inhibits MAPK, is also dependent on an active site Cys (Brondello et al., 1995) .
While the ErbB protein expression and activation data are important for the studies presented, certain caveats have to be applied to their interpretation. The Figure 6 The eects of ErbB1 and ErbB2 function on EGF-and radiation-induced ErbB activation in MDA cells. For either tyrphostin AG1478 or AG825, incubation conditions were 5 mM inhibitor for 30 min prior to treatment with 10 ng/ml EGF or 2 Gy or radiation. Cell lysates were obtained at 2 (radiation) or 5 (EGF) min after initiation of treatment; ErbB immunoprecipitates were collected, fractionated and the resulting Western blots analysed for phospho-Tyr as a measure of activation. The blots shown in (a) and (b) are representative of nine separate experiments. The results from these nine experiments on the eects of radiation and AG825 are tabulated in the bar graph (d) as averages+s.e. with each experiment normalized relative to the phospho-Tyr level on the untreated control. The P values were calculated by the student's t-test. The blots in (c) showing that AG825 inhibits radiationinduced ErbB2 Tyr phosphorylation are representative of four separate experiments evaluation of dierent ErbB protein expression levels within a given cell line using immunochemical techniques may not re¯ect precisely the actual expression levels because of mAb characteristics and other parameters that in¯uence the absolute signal used to quantify the protein. Therefore, comparing expression levels of dierent ErbB receptors in a given cell line is less reliable than the relative quantitation of the same ErbB receptor in dierent cell lines. Another consideration is that the relative expression levels of ErbB proteins may depend on culture conditions and the duration of continuous culture (Gulliford et al., 1997; Todd et al., 1999) . Despite these caveats our ®ndings support the concept that in autocrine growth regulated carcinoma cells at least one of the ErbB receptors with GF binding speci®city and an active kinase domain, such as ErbB1 or ErbB4, are dominantly expressed. For the quantitative evaluation of the relative activation levels of ErbB receptors, as assessed by Tyr phosphorylation, methodological details similar to those described above have to be kept in mind. Thus, most reliable are the increases in Tyr phosphorylation of a given ErbB molecule in the same cell after treatment with GF or radiation.
We have concentrated in this study on the relative interactions of ErbB1 or ErbB4 with ErbB2. The experimental approach is to selectively inhibit the catalytic function of the ErbB molecules and to examine eects on downstream targets. The results establish important links between dierent ErbB receptor interactions and downstream responses that aect cellular radiosensitivity, such as MAPK (Abbott and Holt, 1999; Park et al., 1999; . Tryphostins with speci®cities for the dierent ErbB receptors were used for reasons of experimental consistency and¯exibility in manipulating ErbB receptor functions. Although the use of chemical inhibitors is not without problems, our previous studies demonstrated that the eects of AG1478 on ErbB1 and its downstream eectors are identical to those observed after expression of the dominant negative EGFR-CD533 Reardon et al., 1999; Redemann et al., 1992) . Furthermore, the experimental analyses (Figure 6 ) on the relative eects of the tyrphostins on ErbB1 and ErbB2 Tyr phosphorylation are consistent with the selectivities of AG1478 for ErbB1 and AG825 for ErbB2.
It has been proposed that the constitutively active ErbB2 has a positive modulating eect on other ErbB receptors (Alimandi et al., 1995 (Alimandi et al., , 1997 Earp et al., 1995) . However, limited information exists regarding the details of such response modulation (Gulliford et al., 1997), and the results presented here suggest more complex mechanisms. Indeed our observation of enhanced Tyr phosphorylation of ErbB1 after inhibition of ErbB2 is the opposite to what one would predict if ErbB2 acts as a heterodimerization partner to enhance signals of GF-binding ErbB receptors, such as ErbB1 or ErbB4. One reason for the dierence in ®ndings may be that previous studies concentrated on intrinsic growth regulatory events whereas our studies examine immediate responses to the extrinsically added GF or ionizing radiation. Our data suggests that, in these situations, the inhibition or ErbB2 function and its elimination as a dimerization partner leads to enhanced activation of ErbB1, most likely due to preferred homodimerization. The biological consequence of this response is exempli®ed by a marked modi®cation of the MAPK response in MDA cells leading to an ampli®cation and prolongation of the MAPK activation. The analogous roles of ErbB1 and ErbB4 in MDA and T47D cells, respectively, are supported by similar modi®cations of the radiation and HRG responses under conditions of ErbB4 and ErbB2 inhibition in T47D cells. The data also supports the dominant role of ErbB1 and ErbB4 receptor activation in signals along the MAPK pathway .
Since the ErbB1 catalytic function is required for radiation-induced MAPK activation (Schmidt-Ullrich et al., 1997), we expected that treatment of cells with AG825 would also enhance radiation-stimulated ErbB1 Tyr phosphorylation. Instead, AG825 increased the basal ErbB1 Tyr phosphorylation without signi®cant enhancement in the radiation or GF components. One explanation for this apparent discrepancy in the eects of AG825 on radiation-stimulated ErbB1 and MAPK activities is that the global enhancement in phosphorylation of the ®ve major ErbB1 autophosphorylation sites can obscure changes in the phosphorylation state of the yet unidenti®ed site required for ErbB1-dependent MAPK activation (e.g. Biscardi et al., 1999) . Alternatively, ErbB1-dependent Ras/MAPK signaling can occur by mechanisms not requiring autophosphorylation as shown for ErbB1 lacking the ®ve major Tyr phosphorylation sites (Gotoh et al., 1997; Li et al., 1994; Sasaoka et al., 1996) and for c-Src sensitive sites of ErbB1 (Biscardi et al., 1999) . There is evidence that this auxiliary pathway is dependent upon interactions between ErbB1 and ErbB2 (Sasaoka et al., 1996) . These mechanisms of relative enhancement from the membrane associated receptor(s) to the cytoplasmic MAPK are currently being investigated in more detail.
The pleiotropic eects of MAPK on nuclear regulatory events emphasize the relative importance of upstream regulatory functions of ErbB RTKs. The MAPK pathway is known to modulate the phosphorylation and DNA binding abilities of several downstream transcription factors, including members of the Ets- (Dent et al., unpublished) and AP-1 transcription factor families (Fowles et al., 1998; Wang and Prywes, 2000) . Thus, it is reasonable to hypothesize that inhibition of ErbB2 will, after radiation exposure, increase transcription of Ets-and AP-1-responsive genes and, secondarily, of important cell cycle regulators, such as the cyclin kinase inhibitor p21
Cip-1/WAF1 (Beier et al., 1999; Park et al., 2000) . In addition, the protein expression levels of multiple transcription factors have also been suggested to depend on MAPK signaling (Aubert et al., 1999; Chen et al., 2000; Sears et al., 1993) . For example, we recently demonstrated that inhibition of MAPK in MDA cells rapidly reduced the protein levels of c-Jun .
In summary, this manuscript describes for the ®rst time that ErbB RTK expression pro®les of human carcinoma cells can in¯uence ErbB receptor activation in response to ionizing radiation and GF. The distinctly dierent responses of ErbB receptors translate into distinct MAPK activation patterns that may have important consequences for cellular responses to ligands or radiation. Since ErbB RTKs through MAPK mediate an important cytoprotective response to radiation (Schmidt-Ullrich et al., 1997; Contessa et al., 1998; Reardon et al., 1999) , a more detailed understanding of the relative roles of dierent ErbB molecules in cellular responses to radiation is important for targeted and mechanism-based therapeutic intervention.
Materials and methods
Reagents
Unless speci®ed otherwise, all reagents were obtained from Sigma Chemical Co. (St. Louis, MO, USA). Tyrphostin protein kinase inhibitors, AG1478 and AG825, with speci®-cities for ErbB1/ErbB4 and ErbB2, respectively, were from Calbiochem (San Diego, CA, USA).
Antibodies, growth factors, and inhibitors
The monoclonal antibodies (mAb) used for the immunoprecipitation of ErbB1 (Ab-5) and detection of phospho-Tyr (Ab-2) levels were obtained from Calbiochem (CalbiochemNovabiochem International; San Diego, CA, USA). MAbs used for the immunoprecipitation of ErbB2 (Ab-11), ErbB3 (Ab-4), and ErbB4 (Ab-1), as well as those used for Western blot detection of ErbB1, -2, -3, and -4, Ab-14, Ab-10, Ab-7, and Ab-4, respectively, were obtained from Neomarkers (Fremont, CA, USA). The secondary Ab, an anti-mouse alkaline phosphatase conjugate, was from Promega (Madison, WI, USA). Transforming growth factor-a (TGF-a) was from Oncogene Sciences (Uniondale, NY, USA), and EGF was purchased from Sigma Chemical Co. (St. Louis, MO, USA) and heregulin a1 (HRG) from Neomarkers (Fremont, CA, USA).
Maintenance of cells
A431 human SCCs and MDA-MB-231 (MDA) and T47D human MCCs were obtained from the American Type Tissue Collection (ATTC; Rockville, MD, USA). A431 and T47D cells were maintained in RPMI-1640 supplemented with 10% fetal bovine serum (RPMI/10%FBS) and MDA cells were maintained in RPMI/5%FBS; routine antibiotics were 1000 units/ml penicillin and 1 mg/ml streptomycin. Mycoplasma testing was performed monthly.
Cells were stored as mycoplasma-negative frozen stocks at 7808C. To assure consistent radiation and GF responses, cells were derived from frozen stocks and maintained in continuous culture for maximally 6 weeks; thus, experiments were performed between weeks 2 and 6 after thawing (Schmidt-Ullrich et al., 1996 .
Treatment of cells with EGF and radiation
For all protein and kinase assays, cell culture conditions were maintained as previously described Schmidt-Ullrich et al., 1997) . Prior to exposure to EGF at 10 ng/ml or to 2 Gy of ionizing radiation, cells were maintained in RPMI/0.5%FBS for 24 h. Irradiation was at a dose rate 1.1 Gy/min using a Co-60 source. Similarly, cells were exposed to EGF at speci®ed concentrations 5 min prior to quantitation of ErbB1 phospho-Tyr levels and MAPK activity. For studies involving AG1478 and AG825, cells were pre-incubated with the inhibitor at concentrations of 5 mM for 30 min prior to exposures to EGF or radiation. These drug concentrations and incubation conditions were developed in earlier titration studies unpublished data) that demonstrated the desired speci®city and correspond to the relative inhibitor constants de®ned in vitro for the two tyrphostins (Levitzki and Gazit, 1995; Tsai et al., 1996) .
Immunoprecipitation
Immunoprecipitation of ErbB receptors and MAPK was performed as previously described Reardon et al., 1999) . After treatment, cells were rinsed once with ice-cold PBS and snap-frozen on dry ice. Cell lysates were prepared in 25 mM Tris, pH 7.4, 50 mM bGP, 1.5 mM EGTA, 0.5 mM EDTA, 1.0 mM sodium pyrophosphate, 1.0 mM sodium vanadate, 10 mg/ml leupeptin, 10 mg/ml aprotinin, 1 mM benzamidine, 100 mg/ml PMSF, 1% Triton. Cell lysates were normalized according to protein concentrations using the BCA kit (BioRad; Hercules, CA, USA). For immunoprecipitation of ErbB molecules, equal amounts of cell lysate were incubated with the respective mAb with gentle agitation for 1.5 h at 48C, 50 ml of protein A-agarose (BioRad; Hercules, CA, USA) added, and reacted for an additional 45 min. The agarose was washed twice with icecold lysis buer and boiled in 50 ml sample buer, 5% glycerol, 4% SDS, 144 mM b-mercaptoethanol, 100 mM Tris, pH 6.8. Samples were subjected to immediate SDS-polyacrylamide gel electrophoresis or stored at 7808C. For the quantitation of kinases, the immune complexes were washed with assay buer prior to the assay.
Western blotting
Samples were boiled again upon thawing and fractionated in 6% SDS-polyacrylamide gels. Electrophoresis at 130 V for 2 h was followed by overnight transfer to nitrocellulose membranes (Micron Separations Inc.; Westborough, MA, USA). Blots were blocked in 0.05% Tween/PBS (TPBS) supplemented with 3% blotting grade milk (BioRad; Hercules, CA, USA) for 2 h, and reacted with secondary mAb in the same TPBS/3% milk mixture. Blots were then washed in TPBS and treated with anti-mouse alkaline phosphatase-conjugated Ab. Detection was by CDP-Star Chemiluminescence (Tropix; Bedford, MA, USA). Relative levels of protein expression and ErbB receptor Tyr phosphorylation were quanti®ed using Microsoft Scanwin TM .
Immune complex assays for MAPK activity
The assay for MAPK activity has also been previously described . Brie¯y, immunoprecipitates were incubated with 40 ml H 2 0 containing the appropriate substrates, namely 20 mg of myelin basic protein (MBP) for MAPK. The kinase reaction was initiated by addition of 10 ul of 56 kinase buer (125 mM b-glycerophosphate, pH 7.4, 75 mM ATP, and g[ 32 P]-ATP) and continued at 378C for 30 min. Incorporation of 32 P into MBP was quanti®ed by adsorption to P81 followed by liquid scintillation spectroscopy .
Bistatistical analyses
For all the outcomes, an F test for equality of the variances of the two samples was performed. If the variances were equal, two sample Student's t-test was performed. If the variances were unequal, a Welch modi®ed two sample Student's t-test was performed.
